Medigene announces capital increase of new shares

Planegg - NOT FOR DISTRIBUTION, PUBLICATION OR FORWARDING IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA

Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced the launch of a capital increase by private placement of new shares to institutional investors via an accelerated book building.

The Company expects to issue up to 1,964,599 new shares from authorized capital, which represents approximately 9.7% of the currently outstanding share capital. The shares will be issued excluding pre-emptive rights and are expected to be admitted to listing on the Frankfurt Stock Exchange following their issuance. Book building will commence immediately. It is anticipated that books will close on May 05 before the opening of the Frankfurt Stock Exchange, although the bookrunners reserve the right to close the books at any time. Shares owned by members of the Executive Management Board and Supervisory Board as well as their controlled or associated companies will be subject to a customary 90-day lock-up provision upon completion of the transaction.

Medigene intends to use the net proceeds of this placement to intensify the Company's Research & Development activities in order to expand its planned clinical program for T-cell receptor (TCR) modified T cells into additional regions and indications as soon as possible.

Prof. Dolores Schendel, Chief Executive Officer of Medigene comments: "Medigene has successfully implemented its transformation into an immunotherapy company with a phase II study for DC vaccines running and the clinical development of our TCR therapy to get started this year. The proceeds from this offering will support our plans to generate comprehensive clinical data for that innovative therapeutic approach as fast as possible paving the path for further development options."

Guggenheim Securities, LLC and Baader Bank AG are acting as the bookrunners for the capital increase. Trout Capital LLC is also acting as a placement agent for the transaction.

Note: This press release does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States, Germany or any other jurisdiction. The shares (the "Shares") of Medigene AG (the "Company") may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of Shares in the Company in the United States.

This publication constitutes neither an offer to sell nor a solicitation to buy securities.

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.